Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:category |
antineoplastic agent
|
| gptkbp:contains |
antimony in +5 oxidation state
|
| gptkbp:contraindication |
renal impairment
severe cardiac disease |
| gptkbp:discoveredIn |
20th century
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pentavalent antimonials
|
| gptkbp:includes |
gptkb:sodium_stibogluconate
meglumine antimoniate |
| gptkbp:mechanismOfAction |
unknown
|
| gptkbp:routeOfAdministration |
intramuscular
intravenous |
| gptkbp:sideEffect |
pancreatitis
arthralgia myalgia cardiotoxicity |
| gptkbp:usedFor |
leishmaniasis
|
| gptkbp:WHOModelListOfEssentialMedicines |
gptkb:sodium_stibogluconate
meglumine antimoniate |
| gptkbp:bfsParent |
gptkb:Leishmania_parasites
|
| gptkbp:bfsLayer |
7
|